Cargando…
Can We Trust Safety of Tenofovir Disoproxil in Patients with Decompensated Cirrhosis?
Autores principales: | Oh, Hyunwoo, Jun, Dae Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of Gut and Liver
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669588/ https://www.ncbi.nlm.nih.gov/pubmed/29081210 http://dx.doi.org/10.5009/gnl17401 |
Ejemplares similares
-
Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
por: Lee, Soon Kyu, et al.
Publicado: (2017) -
Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021) -
Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
por: Yim, Hyung Joon, et al.
Publicado: (2022) -
Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study
por: Chang, Young, et al.
Publicado: (2021) -
Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis
por: Zhang, Ping, et al.
Publicado: (2018)